Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Azixa

3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)

Trial Locations (10)

10032

Columbia University, New York

60611

Northwestern University, Chicago

85013

Barrow Neurological Institute, Phoenix

90048

Cedars-Sinai Medical Center, Los Angeles

94305

Stanford University, Stanford

981209

SCCA/University of Washington, Seattle

02111

Tufts Medical Center, Boston

01805

Lahey Clinic, Burlington

01655

University of Massachusettes, Worcester

03756

Darthmouth -Hitchcock Medical Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT00892931 - Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter